Stromal Cell – Derived Factor-1 A and CXCR 4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma : von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor

The genetic hallmark of hemangioblastomas and clear cellrenal cell carcinomas (CC-RCCs) is loss-of-function of the von Hippel-Lindau (VHL) tumor suppressor protein. VHL is required for oxygen-dependent degradation of hypoxiainducible factor-1A (HIF-1A). In hemangioblastomas and CC-RCCs, HIF-1A is constitutively overexpressed leading to increased transcription of HIF-1–regulated genes, including vascular endothelial growth factor (VEGF). Because loss of VHL function is associated with increased expression of the chemokine receptor CXCR4 in CC-RCCs, we investigated the expression of HIF-1A, CXCR4, and its ligand stromal cell– derived factor-1A (SDF-1A) in hemangioblastomas and CCRCCs. Immunohistochemistry revealed overexpression of both CXCR4 and SDF-1A within tumor cells and endothelial cells of hemangioblastomas and CC-RCCs. HIF-1A was detected in tumor cell nuclei of both hemangioblastomas and CC-RCCs. A specific ELISA showed that hemangioblastomas and CC-RCCs expressed SDF-1A protein at levels that were significantly higher than those found in normal tissue. Analysis of the VHL-null RCC line 786-0 revealed that SDF-1A mRNA levels were 100-fold higher than in a subclone transfected with the wild-type VHL gene. Expression of CXCR4 and SDF-1A mRNA was significantly decreased in HIF-1A-null compared with wild-type mouse embryo fibroblasts (MEFs). ELISA and Western blot studies for SDF-1A and CXCR4 protein expression confirmed the RNA findings in RCC lines and MEFs. These results suggest that loss-of-function of a single tumor suppressor gene can up-regulate the expression of both a ligand and its receptor, which may establish an autocrine signaling pathway with important roles in the pathogenesis of hemangioblastoma and CC-RCC. (Cancer Res 2005; 65(14): 6178-88)

[1]  S. Moorthy,et al.  Von Hippel-Lindau disease , 2002, Definitions.

[2]  Lieve Moons,et al.  CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. , 2005, Cancer research.

[3]  D. Ornstein Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs , 2004 .

[4]  Geoffrey C Gurtner,et al.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 , 2004, Nature Medicine.

[5]  Napoleone Ferrara,et al.  Vascular endothelial growth factor: basic science and clinical progress. , 2004, Endocrine reviews.

[6]  R. Strieter,et al.  CXC chemokines in angiogenesis of cancer. , 2004, Seminars in cancer biology.

[7]  Arnon Nagler,et al.  CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. , 2004, Cancer research.

[8]  F. Erdoğan,et al.  Prognostic significance of morphologic parameters in renal cell carcinoma , 2004, International journal of clinical practice.

[9]  F. André,et al.  Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  W Marston Linehan,et al.  Genetic Basis of Cancer of the Kidney , 2006 .

[11]  Brian Keith,et al.  Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation , 2003, Molecular and Cellular Biology.

[12]  S. Saccani,et al.  Regulation of the Chemokine Receptor CXCR4 by Hypoxia , 2003, The Journal of experimental medicine.

[13]  Andrew L Kung,et al.  A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Y. Ko,et al.  The use of suppression subtractive hybridization for the study of SDF-1alpha induced gene-expression in human endothelial cells. , 2003, Molecular and cellular probes.

[15]  G. Semenza Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[16]  H. Moch,et al.  Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.

[17]  E. Messing,et al.  Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas. , 2003, The Journal of urology.

[18]  W. Kaelin,et al.  The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. , 2003, The New England journal of medicine.

[19]  Masahiro Kato,et al.  Expression pattern of CXC chemokine receptor-4 is correlated with lymph node metastasis in human invasive ductal carcinoma , 2003, Breast Cancer Research.

[20]  M. Burdick,et al.  The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. , 2003, American journal of respiratory and critical care medicine.

[21]  K. Pienta,et al.  Expression of CXCR4 and CXCL12 (SDF‐1) in human prostate cancers (PCa) in vivo , 2003, Journal of cellular biochemistry.

[22]  G. Semenzato TARGETING HIF-1 FOR CANCER THERAPY , 2003 .

[23]  W. Kaelin,et al.  VHL and kidney cancer. , 2003, Methods in molecular biology.

[24]  C. Hitchon,et al.  Hypoxia-induced production of stromal cell-derived factor 1 (CXCL12) and vascular endothelial growth factor by synovial fibroblasts. , 2002, Arthritis and rheumatism.

[25]  M. Mori,et al.  Regional Expression of CXCL12/CXCR4 in Liver and Hepatocellular Carcinoma and Cell‐cycle Variation during in vitro Differentiation , 2002, Japanese journal of cancer research : Gann.

[26]  A. Harris,et al.  Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation. , 2002, Cancer research.

[27]  M. Probst-Kepper,et al.  CXCR4/CXCL12 expression and signalling in kidney cancer , 2002, British Journal of Cancer.

[28]  Lei Yao,et al.  Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1. , 2002, Blood.

[29]  H. Gröne,et al.  Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. , 2001, Cancer research.

[30]  M. Ivan,et al.  HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O2 Sensing , 2001, Science.

[31]  J. Soria,et al.  SDF-1 activity on microvascular endothelial cells: consequences on angiogenesis in in vitro and in vivo models. , 2000, Thrombosis research.

[32]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[33]  A. Alfranca,et al.  Up-regulation of vascular endothelial growth factor receptor Flt-1 after endothelial denudation: role of transcription factor Egr-1. , 2000, Blood.

[34]  G. Semenza,et al.  Expression of hypoxia-inducible factor 1alpha in brain tumors: association with angiogenesis, invasion, and progression. , 2000, Cancer.

[35]  S. Dudas,et al.  Identification and localization of the cytokine SDF1 and its receptor, CXC chemokine receptor 4, to regions of necrosis and angiogenesis in human glioblastoma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[37]  J. Pevsner,et al.  Detection of endogenous biotin in various tissues: novel functions in the hippocampus and implications for its use in avidin-biotin technology , 1999, Cell and Tissue Research.

[38]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[39]  G. Semenza,et al.  Advances in Brief Reciprocal Positive Regulation of Hypoxia-inducible Factor 1 a and Insulin-like Growth Factor 21 , 1999 .

[40]  K. Plate,et al.  Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function , 1998 .

[41]  S. Rafii,et al.  The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. , 1998, Blood.

[42]  Kouji Matsushima,et al.  The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract , 1998, Nature.

[43]  Campello,et al.  Haemangioblastoma of the central nervous system in von Hippel–Lindau disease , 1998, Journal of internal medicine.

[44]  W. Linehan,et al.  Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. , 1998, Cancer research.

[45]  M. Volin,et al.  Chemokine receptor CXCR4 expression in endothelium. , 1998, Biochemical and biophysical research communications.

[46]  Rakesh K. Jain,et al.  Interstitial pH and pO2 gradients in solid tumors in vivo: High-resolution measurements reveal a lack of correlation , 1997, Nature Medicine.

[47]  R. Klausner,et al.  Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[48]  W. Kaelin,et al.  Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  J. Sodroski,et al.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry , 1996, Nature.

[50]  G. Semenza,et al.  Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.

[51]  R. Warnke,et al.  Suppression of endogenous avidin-binding activity in tissues and its relevance to biotin-avidin detection systems. , 1981, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.